Clinical Trials Browser

Active not recruiting × Everolimus × 1 year × Clear all

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Carcinoma, Renal Cell

Endometrial Hyperplasia

Breast Neoplasms, Recurrence

Thyroid cancer, Hurthle cell

Endometrial Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Seizures, Tuberous Sclerosis

Tuberous Sclerosis, Angiomyolipoma

Breast Neoplasms

Breast Neoplasms

Advanced Cancer

Breast Neoplasms

Neoplasm Metastasis

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Recurrence, Endometrial Neoplasms

Endometrial Neoplasms

Advanced Solid Tumors

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Thyroid Diseases, Thyroid Neoplasms

Breast Neoplasms, Endometrial Neoplasms

Neuroendocrine Tumors

Primary Non-metastatic Breast Cancer

Carcinoma, Renal Cell, Kidney Neoplasms

Leiomyosarcoma, Liposarcoma, Sarcoma

Clinical Trials

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

CLEAR

LEVER

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

e3

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

COMPOSE

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

EMBER

COMPETE

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)